Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Therapy-Induced Cellular Senescence in Non-Hodgkin Lymphomas, with Emphasis on Aggressive B-Cell Subtypes: Molecular Mechanisms and Emerging Drug Targets.

Current cancer drug targets·2026

Same author

Machine Learning-Driven Probability of Permanent Pacemaker Implantation After Transcatheter Aortic Valve Replacement.

Diagnostics (Basel, Switzerland)·2026

Same author

When atrioventricular block paves the way to a more severe diagnosis: a case report.

European heart journal. Case reports·2026

Same author

Triple-Valve Infective Endocarditis.

Balkan medical journal·2026

Same author

Cardiopulmonary Functional Profiles in Cancer Therapy-Related Cardiac Dysfunction Among Patients with Non-Hodgkin Lymphoma.

Diagnostics (Basel, Switzerland)·2025

Same author

Diabetes mellitus as a risk factor and comorbidity in gout.

Folia medica·2024

Search research articles

Related Experiment Video

Updated: Jan 7, 2026

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Integrated Model for Predicting Cancer Therapy-Related Cardiac Dysfunction in Non-Hodgkin Lymphoma.

Daniela Bursacovschi¹, Oleg Arnaut^2,3,4, Viorica Ochisor⁵

¹Department of Heart Failure, Public Healthcare Institution-Institute of Cardiology, MD-2025 Chisinau, Moldova.

|December 30, 2025

Summary

A new predictive model accurately identifies patients with non-Hodgkin lymphoma (NHL) at risk for cancer therapy-related cardiac dysfunction (CTRCD). This tool aids early detection and intervention for cardiotoxicity in NHL patients.

Keywords:

cancer treatment chemotherapy-related cardiac dysfunction heart failure prediction model

More Related Videos

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Related Experiment Videos

Last Updated: Jan 7, 2026

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Area of Science:

Cardiology
Oncology
Cardio-oncology

Background:

Cancer Therapy-Related Cardiac Dysfunction (CTRCD) is a significant complication in non-Hodgkin lymphoma (NHL) patients.
CTRCD can lead to severe cardiovascular events, including heart failure.
Early identification of at-risk patients is critical for timely intervention.

Purpose of the Study:

To develop and validate a predictive model for CTRCD in NHL patients.
To assess early subclinical cardiac changes associated with chemotherapy.

Main Methods:

A prospective cohort study of 127 adult NHL patients over 6 months.
Utilized echocardiography, cardiorespiratory exercise testing, 24-h Holter monitoring, and cardiac biomarkers (troponin I, NT-proBNP).

Main Results:

A predictive model for CTRCD achieved 94.2% accuracy and strong discriminative ability (AUC 0.95).
Key predictors included baseline SDNNi, heart rate, doxorubicin dose, NT-proBNP, QT interval, hemoglobin, age, left atrial volume, and diastolic function.
Lower cardiopulmonary reserve was linked to increased CTRCD risk.

Conclusions:

The developed model is a practical and robust tool for assessing CTRCD risk in NHL patients.
Facilitates early detection and management of chemotherapy-induced cardiotoxicity.